

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mark J. Ratain et al.

Serial No.: 10/751,606

Filed: January 5, 2004


For: OPTIMIZATION OF CANCER
TREATMENT WITH IRINOTECAN

Group Art Unit: 1634

Examiner: Sarae L. Bausch

Atty. Dkt. No.: ARCD:389US

Confirmation No.: 2944

CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this communication is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below.	
October 24, 2007 Date	 Steven C. Highlander

OFFICE COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Commissioner:

This paper is being electronically filed in support of an Inventors' Declaration Under 37 C.F.R. § 1.132, previously referenced in applicant's response filed January 26, 2007.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:389US/SLH.

A courtesy copy of this filing has been faxed to the examiner. The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: October 24, 2007